BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31558918)

  • 1. Promoter Hypomethylation Is Responsible for Upregulated Expression of HAI-1 in Hepatocellular Carcinoma.
    Du X; Wu L; Ur Rahman MS; Teng X; Teng L; Ye J; Cao J
    Dis Markers; 2019; 2019():9175215. PubMed ID: 31558918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocyte growth factor activator inhibitor 2/placental bikunin (HAI-2/PB) gene is frequently hypermethylated in human hepatocellular carcinoma.
    Fukai K; Yokosuka O; Chiba T; Hirasawa Y; Tada M; Imazeki F; Kataoka H; Saisho H
    Cancer Res; 2003 Dec; 63(24):8674-9. PubMed ID: 14695180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter hypomethylation up-regulates CD147 expression through increasing Sp1 binding and associates with poor prognosis in human hepatocellular carcinoma.
    Kong LM; Liao CG; Chen L; Yang HS; Zhang SH; Zhang Z; Bian HJ; Xing JL; Chen ZN
    J Cell Mol Med; 2011 Jun; 15(6):1415-28. PubMed ID: 20629990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma.
    Li H; Zhang M; Linghu E; Zhou F; Herman JG; Hu L; Guo M
    Clin Epigenetics; 2018 Nov; 10(1):137. PubMed ID: 30400968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma.
    Qiu W; Zhou B; Zou H; Liu X; Chu PG; Lopez R; Shih J; Chung C; Yen Y
    Am J Pathol; 2004 Nov; 165(5):1689-99. PubMed ID: 15509538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
    Li Z; Zhang H; Yang J; Hao T; Li S
    Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of hepatocyte growth factor activator and hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma.
    Nagata K; Hirono S; Ido A; Kataoka H; Moriuchi A; Shimomura T; Hori T; Hayashi K; Koono M; Kitamura N; Tsubouchi H
    Biochem Biophys Res Commun; 2001 Nov; 289(1):205-11. PubMed ID: 11708800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus X protein promotes P3 transcript expression of the insulin-like growth factor 2 gene via inducing hypomethylation of P3 promoter in hepatocellular carcinoma.
    Tang S; Hu W; Hu J; Wu S; Li J; Luo Y; Cao M; Zhou H; Jiang X
    Liver Int; 2015 Feb; 35(2):608-19. PubMed ID: 24423280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hepatitis B virus X protein promotes insulin-like growth factor II gene expression by inducing hypomethylation of the P3 promoter in hepatocellular carcinoma].
    Tang S; Zhang S; Zhang X; Wu S; Li J; Jiang X; Zhou H; Luo Y; Cao M
    Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):289-94. PubMed ID: 25173229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of aberrant cyclin-dependent kinase-like 2 methylation in hepatocellular carcinoma.
    Zhou Y; Qiu XP; Li ZH; Zhang S; Rong Y; Yang GH; Fang-Zheng
    Gene; 2019 Jan; 683():35-40. PubMed ID: 30292871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced T-cadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma.
    Yan Q; Zhang ZF; Chen XP; Gutmann DH; Xiong M; Xiao ZY; Huang ZY
    Int J Oncol; 2008 May; 32(5):1057-63. PubMed ID: 18425332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HAI-2 is epigenetically downregulated in human hepatocellular carcinoma, and its Kunitz domain type 1 is critical for anti-invasive functions.
    Tung EK; Wong CM; Yau TO; Lee JM; Ching YP; Ng IO
    Int J Cancer; 2009 Apr; 124(8):1811-9. PubMed ID: 19107935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHD5 a tumour suppressor is epigenetically silenced in hepatocellular carcinoma.
    Zhao R; Wang N; Huang H; Ma W; Yan Q
    Liver Int; 2014 Jul; 34(6):e151-60. PubMed ID: 24529164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma and postoperative outcomes.
    Funagayama M; Kondo K; Chijiiwa K; Kataoka H
    World J Surg; 2010 Jul; 34(7):1563-71. PubMed ID: 20213201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of possible mechanisms accounting for raf-1 kinase inhibitor protein downregulation in hepatocellular carcinoma.
    Poma P; Labbozzetta M; Vivona N; Porcasi R; D'Alessandro N; Notarbartolo M
    OMICS; 2012 Nov; 16(11):579-88. PubMed ID: 23095110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma.
    Guo Y; Peng Y; Gao D; Zhang M; Yang W; Linghu E; Herman JG; Fuks F; Dong G; Guo M
    Clin Epigenetics; 2017; 9():116. PubMed ID: 29075359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and promoter methylation of hDAB2IPA in hepatocellular carcinoma.
    Qiu GH; Xie H; Wheelhouse N; Harrison D; Chen GG; Salto-Tellez M; Lai P; Ross JA; Hooi SC
    J Hepatol; 2007 Apr; 46(4):655-63. PubMed ID: 17258345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C/EBPalpha is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation.
    Lu GD; Leung CH; Yan B; Tan CM; Low SY; Aung MO; Salto-Tellez M; Lim SG; Hooi SC
    Gastroenterology; 2010 Aug; 139(2):632-43, 643.e1-4. PubMed ID: 20347819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification by TCGA database search of five genes that are aberrantly expressed and involved in hepatocellular carcinoma potentially via DNA methylation changes.
    Matsushita J; Suzuki T; Okamura K; Ichihara G; Nohara K
    Environ Health Prev Med; 2020 Jul; 25(1):31. PubMed ID: 32703154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
    Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
    J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.